Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to slow advanced breast cancer growth

NCT ID NCT05296798

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This study tests whether adding the drug giredestrant to standard treatment (Phesgo) can help people with advanced HER2-positive, estrogen receptor-positive breast cancer live longer without their cancer getting worse. About 922 participants who have not had prior treatment for advanced disease will receive either the combination or Phesgo alone. The main goal is to see if the combination delays cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 922 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2022

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or cytologically confirmed and documented human epidermal growth factor receptor 2 (HER2)-positive/estrogen receptor (ER)-positive adenocarcinoma of the breast with metastatic or locally-advanced disease not amenable to curative resection * At least one measurable lesion and/or non-measurable disease evaluable according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence of ≥6 months * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Left ventricular ejection fraction (LVEF) of at least (≥)50% measured by echocardiogram (ECHO) or multiple-gated acquisition scan (MUGA) * Adequate hematologic and end-organ function * For women of childbearing potential: Participants who agree to remain abstinent (refrain from heterosexual intercourse) or use contraception, and agree to refrain from donating eggs, during the treatment period and for 7 months after the final dose of Phesgo * For men: participants who agree to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agree to refrain from donating sperm, during the treatment period and for 7 months after the final dose of Phesgo to avoid exposing the embryo Maintenance Phase Inclusion Criteria * Complete a minimum of four cycles to a maximum of eight cycles of induction therapy; the minimum cycles are defined as either: Phesgo injections + 4 docetaxel infusions, or Phesgo injections + 12 paclitaxel infusions * Achieve a minimum of stable disease (SD) (or Non-complete response \[CR\]/Non-progressive disease \[PD\] for participants with non-measurable disease) (i.e., did not experience PD) according to RECIST v1.1 at the last tumor assessment during the induction therapy phase * LVEF of ≥50% at the last assessment during the induction therapy phase Exclusion Criteria: * Previous systemic non-hormonal anti-cancer therapy in the metastatic breast cancer (MBC) or advanced breast cancer (ABC) setting. Note: Up to one line of single-agent endocrine therapy given in the metastatic or locally advanced setting will be allowed. * Prior treatment with a selective estrogen receptor degrader (SERD) * Previous treatment with approved or investigative anti-HER2 agents in any breast cancer treatment setting, except Phesgo (or trastuzumab SC with pertuzumab IV, or pertuzumab and trastuzumab IV), single-agent trastuzumab IV or SC, ado-trastuzumab emtansine, lapatinib, and neratinib in the neoadjuvant or adjuvant setting * Disease progression within 6 months of receiving adjuvant anti-HER2 therapy (such as trastuzumab, with or without pertuzumab \[IV, SC, or fixed-dose combination\], or ado-trastuzumab emtansine, or neratinib) * Non-resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) Grade 1 or better * History of persistent Grade ≥2 (NCI-CTC, Version 5.0) hematological toxicity resulting from previous adjuvant or neo-adjuvant therapy * History of exposure to the following cumulative doses of anthracyclines; Doxorubicin \>360 mg/m2; Liposomal doxorubicin \>500 mg/m2; Epirubucin \>720 mg/m2; Mitoxantrone \>120 mg/m2; Idarubicin \>90 mg/m2. * Known active uncontrolled or symptomatic central nervous system (CNS) metastases, carcinomatous meningitis, or leptomeningeal disease * Dyspnea at rest due to complications of advanced malignancy, or other disease requiring continuous oxygen therapy * Pregnant or breastfeeding, or intending to become pregnant during the study or within 7 months after the final dose of Phesgo (Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of induction therapy). * Treated with investigational therapy within 28 days prior to initiation of induction therapy * Treated with localized palliative radiotherapy within 14 days prior to initiation of induction therapy * Concurrent participation in any other therapeutic clinical trial * Known hypersensitivity to any of the study medications or to excipients of recombinant human or humanized antibodies * Current chronic daily treatment (continuous for \>3 months) with corticosteroids (dose of 10 mg/day methylprednisolone or equivalent) * Poorly controlled hypertension * Known clinically significant history of liver disease consistent with Child-Pugh Class B or C, active liver disease including active viral or other hepatitis virus, autoimmune hepatic disorders, or sclerosing cholangitis, current alcohol abuse, or cirrhosis * Active cardiac disease or history of cardiac dysfunction * Major surgical procedure or significant traumatic injury within 14 days prior to enrollment or anticipation of need for major surgery during induction therapy * Active inflammatory bowel disease, chronic diarrhea, short bowel syndrome, or major upper gastrointestinal surgery * Concurrent, serious, uncontrolled infections, or known infection with HIV with the following exception: Individuals who are HIV positive are eligible provided they are stable on anti-retroviral therapy for ≥4 weeks, have a CD4 count ≥350 cells/uL, and have an undetectable viral load and no history of AIDS-defining opportunistic infections within 12 months prior to enrollment. * Serious COVID-19 infection within 14 days prior to enrollment; however, no screening testing for SARS-CoV-2 is required * Serious infection requiring oral or IV antibiotics within 7 days prior to screening * Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in the study * History of malignancy within 5 years prior to screening with the exception of the cancer under investigation in this study and malignancies with a negligible risk of metastasis or death * For pre- and perimenopausal women, and men: Known hypersensitivity to luteinizing hormone-releasing hormone agonist (LHRHa); Not willing to undergo and maintain treatment with approved LHRHa therapy for the duration of endocrine therapy that requires gonadal function suppression * Treatment with strong CYP3A4 inhibitors or inducers within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of giredestrant treatment in Arm B * A documented history of hemorrhagic diathesis, coagulopathy, or thromboembolism, including deep vein thrombosis, unless the condition is adequately treated and under control

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Locally advanced or metastatic breast cancer

Contacts and locations

Locations

  • Ac?badem Altunizade Hastanesi

    Istanbul, 34662, Turkey (Türkiye)

  • Adana Baskent University Hospital

    Adana, 01120, Turkey (Türkiye)

  • Affiliated Hospital of Hebei University

    Baoding, 071000, China

  • American University of Beirut - Medical Center

    Beirut, 1107 2020, Lebanon

  • Ankara City Hospital

    Ankara, 06800, Turkey (Türkiye)

  • Ankara Oncology Hospital

    Ankara, 06200, Turkey (Türkiye)

  • Antalya Memorial Hastanesi

    Kepez, 07020, Turkey (Türkiye)

  • Arizona Clinical Research Center, Inc

    Tucson, Arizona, 85715, United States

  • Ars Medical Sp. z o. o.

    Pi?a, 64-920, Poland

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Asst Degli Spedali Civili Di Brescia

    Brescia, Lombardy, 25123, Italy

  • Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department

    Erzurum, 25240, Turkey (Türkiye)

  • Azienda Ospedaliera Universitaria Federico II

    Naples, Campania, 80131, Italy

  • Azienda Unità Sanitaria Locale di Reggio Emilia/IRCCS

    Reggio Emilia, Emilia-Romagna, 42123, Italy

  • Bekes Varmegyei Központi Korhaz, Pandy Kalman Tagkorhaz

    Gyula, 5700, Hungary

  • Blackpool Victoria Hospital

    Blackpool, FY3 8NR, United Kingdom

  • Budapesti Szent Margit Korhaz

    Budapest, 1032, Hungary

  • Burjeel Medical City-Abu Dhabi

    Abu Dhabi, United Arab Emirates

  • CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica

    San Juan, J5400DIL, Argentina

  • CH de la Côte Basque - Hôpital de Bayonne

    Bayonne, 64109, France

  • CHD Vendée

    La Roche-sur-Yon, 85025, France

  • CHRISTUS Spohn Cancer Center - Shoreline

    Corpus Christi, Texas, 78404, United States

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • CHU de GRENOBLE

    Grenoble, 38043, France

  • Cancer Specialists of North Florida

    Jacksonville, Florida, 32256, United States

  • Caritas-Krankenhaus St. Josef

    Regensburg, 93053, Germany

  • Centre Catalan D' Oncologie

    Perpignan, 66000, France

  • Centro Estatal de Cancerologia de Chihuahua

    Chihuahua City, 31000, Mexico

  • Centro Oncologico Korben

    Ciudad Autonoma Buenos Aires, C1426AGE, Argentina

  • Centro Oncologico MD Anderson Internacional

    Madrid, 28033, Spain

  • Centro Oncologico Riojano Integral (CORI)

    La Rioja, F5300COE, Argentina

  • Centro de Investigaciones Médicas y Desarrollo LC S.R.L

    Buenos Aires, Ciudad Autónoma de BuenosAires, C1113AAE, Argentina

  • Centrum Onkologii ? Instytut im. Marii Sk?odowskiej-Curie Klinika Nowotworów Piersi i Chirurgii

    Warsaw, 02-781, Poland

  • Changhua Christian Hospital

    Changhua, 500, Taiwan

  • Charing Cross Hospital

    London, W6 8RF, United Kingdom

  • China Medical University Hospital

    Taichung, 404, Taiwan

  • Clinica Colsanitas S.A. sede Clinica Universitaria Colombia

    Bogotá, 111321, Colombia

  • Clinica De La Costa

    Barranquilla, 080020, Colombia

  • Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda

    São Paulo, São Paulo, 01317-001, Brazil

  • Clinical Research Alliance

    Westbury, New York, 11590, United States

  • Clinique Ste-Elisabeth

    Namur, 5000, Belgium

  • Complejo Hospitalario Universitario de Santiago (CHUS)

    Santiago de Compostela, LA Coruna, 15706, Spain

  • Cuidados oncologicos

    Querétaro City, Querétaro, 76000, Mexico

  • Dar El salam Cancer Centre

    Cairo, Egypt

  • Dicle University Faculty of Medicine

    Diyarbakır, 21280, Turkey (Türkiye)

  • Dres. Andreas Köhler und Roswitha Fuchs

    Langen, 63225, Germany

  • Ege Uni Medical Faculty

    Izmir, 35100, Turkey (Türkiye)

  • Erciyes Uni

    Kayseri, 38039, Turkey (Türkiye)

  • Filios Alta Medicina

    Monterrey, Nuevo León, 64460, Mexico

  • Fortis Hospital

    New Delhi, National Capital Territory of Delhi, 110088, India

  • Fujian Cancer Hospital

    Fuzhou, 350014, China

  • Fundacion Centro Oncologico de Integracion Regional (COIR)

    Mendoza, M5500AYB, Argentina

  • Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo

    Bogota, D.C., 110131, Colombia

  • Fundação Pio XII Hospital de Câncer de Barretos

    Barretos, São Paulo, 14784-400, Brazil

  • GHdC Site Les Viviers

    Charleroi, 6000, Belgium

  • Gangnam Severance Hospital

    Seoul, 06273, South Korea

  • Gazi Uni Medical Faculty Hospital

    Ankara, 06500, Turkey (Türkiye)

  • Gesundheitszentrum Wetterau, Hochwaldkrankenhaus Bad Nauheim

    Bad Nauheim, 61231, Germany

  • Guangxi Cancer Hospital of Guangxi Medical University

    Nanning, 530021, China

  • Health Pharma Professional Research

    Mexico City, Mexico CITY (federal District), 03100, Mexico

  • Hopital Prive Jean Mermoz

    Lyon, 69373, France

  • Hospital Araujo Jorge

    Goiânia, Goiás, 74605-070, Brazil

  • Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia

    Valencia, 46015, Spain

  • Hospital Beatriz Angelo

    Loures, 2674-514, Portugal

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Jalisco, 44280, Mexico

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Hospital Clínic i Provincial

    Barcelona, 08036, Spain

  • Hospital Juan Ramon Jimenez

    Huelva, 21005, Spain

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, 91350-200, Brazil

  • Hospital Provincial del Centenario

    Rosario, S2002KDS, Argentina

  • Hospital Sao Rafael - HSR

    Salvador, Estado de Bahia, 41253-190, Brazil

  • Hospital Universitario

    Monterrey, Nuevo León, 64460, Mexico

  • Hospital Universitario Clínico San Cecilio

    Granada, 18016, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Tenerife, 38320, Spain

  • Hospital Zambrano Hellion TecSalud

    Monterrey, Nuevo León, Mexico

  • Hospital de Amor Amazônia

    Porto Velho, Rondônia, 76834-899, Brazil

  • Hospital de S. Francisco Xavier

    Lisbon, 1495-005, Portugal

  • Hospital do Cancer de Pernambuco - HCP

    Recife, Pernambuco, 50040-000, Brazil

  • Hospital do Câncer de Londrina

    Londrina, Paraná, 86015-520, Brazil

  • Humanitas Centro Catanese Di Oncologia

    Misterbianco (CT), Sicily, 95045, Italy

  • Hunan Cancer Hospital

    Changsha, 410013, China

  • INSTITUT CURIE_Site Paris

    Paris, 75005, France

  • IOV - Istituto Oncologico Veneto - IRCCS

    Padova, Veneto, 35128, Italy

  • IPO de Coimbra

    Coimbra, 3000-075, Portugal

  • IPO do Porto

    Porto, 4200-072, Portugal

  • Iem-Fucam

    D.F., Mexico CITY (federal District), 04980, Mexico

  • Institut Sainte Catherine

    Avignon, 84918, France

  • Instituto de Oncología de Rosario

    Rosario, S2000KZE, Argentina

  • International Cancer Institute (ICI)

    Eldoret, 30100, Kenya

  • Investigacion Oncofarmaceutica

    La Paz, Baja California Sur, 23040, Mexico

  • Istituto Clinico Humanitas

    Rozzano, Lombardy, 20089, Italy

  • Istituto Europeo Di Oncologia

    Milan, Lombardy, 20141, Italy

  • Istituto Nazionale Tumori Irccs Fondazione g. PASCALE

    Naples, Campania, 80131, Italy

  • Izmir Ataturk Training and Research Hospital

    Izmir, 35360, Turkey (Türkiye)

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, 5004, Hungary

  • Jessa Zkh (Campus Virga Jesse)

    Hasselt, 3500, Belgium

  • Jiangsu Cancer Hospital

    Nanjing, 210009, China

  • Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

    Nanjing, 210029, China

  • Jiangxi Cancer Hospital

    Nanchang, 330006, China

  • King Fahad Medical City

    Riyadh, 11525, Saudi Arabia

  • King Faisal Specialist Hospital & Research Centre

    Riyadh, 11211, Saudi Arabia

  • King Hussein Cancer Center

    Amman, 1269, Jordan

  • Kliniken Essen-Mitte

    Essen, 45136, Germany

  • Klinikum Mutterhaus der Borromaeerinnen gGmbH;Gynäkologie

    Trier, 54290, Germany

  • Kocaeli University Faculty of Medicine

    İzmit, 31380, Turkey (Türkiye)

  • Komarom-Eszergom Varmegyei Szent Borbala Korhaz

    Tatabánya, 2800, Hungary

  • Kyungpook National University Chilgok Hospital

    Daegu, 41404, South Korea

  • Los Angeles Hematology Oncology Medical Group

    Los Angeles, California, 90017, United States

  • MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie

    Rzeszów, 35-021, Poland

  • MVZ für Hämatologie und Onkologie Ravensburg GmBH

    Ravensburg, 88212, Germany

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, 50200, Thailand

  • Maidstone Hospital

    Maidstone, ME16 9QQ, United Kingdom

  • Manipal Hospital

    Bangalore, Karnataka, 560017, India

  • Maryland Oncology Hematology - Annapolis

    Annapolis, Maryland, 21401, United States

  • Medical Park Seyhan Hospital

    Seyhan, 01140, Turkey (Türkiye)

  • Mersin City Education and Research Hospital

    Mersin, 33240, Turkey (Türkiye)

  • Namik Kemal Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, 100

    Tekirdağ, 59030, Turkey (Türkiye)

  • National Cancer Center

    Goyang-si, 10408, South Korea

  • National Cancer Institute- Breast Cancer Treatment & Research Hospital - 5th settlement

    Cairo, Egypt

  • National Cheng Kung University Hospital

    Tainan, 00704, Taiwan

  • National Guard King Abdulaziz Medical City

    Riyadh, 11426, Saudi Arabia

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Nationales Centrum für Tumorerkrankungen (NCT)

    Heidelberg, 69120, Germany

  • Netaji Subhas Chandra Bose Cancer Hospital

    Kolkata, West Bengal, 700094, India

  • No. 900 Hospital (Fuzhou General Hospital)

    Fuzhou, 350009, China

  • North Wales Cancer Treatment Centre, Glan Clwyd Hospital

    Rhyl, LL18 5UJ, United Kingdom

  • Nottingham University Hospitals NHS Trust - City Hospital

    Nottingham, NG5 1PB, United Kingdom

  • Oncologico Potosino

    San Luis Potosí City, San Luis Potosí, 78209, Mexico

  • Oncomedica S.A.

    Montería, 230002, Colombia

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, 98700-000, Brazil

  • Oncólogos de Occidente

    Pereira, 600004, Colombia

  • Ondokuz Mayis Univ. Med. Fac.

    Samsun, 55139, Turkey (Türkiye)

  • Opolskie Centrum Onkologii

    Opole, 45-060, Poland

  • Ospedale Civile

    Livorno, Tuscany, 57100, Italy

  • Ospedale Infermi AUSL della Romagna

    Rimini, Emilia-Romagna, 47900, Italy

  • Peking University People's Hospital

    Beijing, 100044, China

  • Policlinico Universitario Agostino Gemelli

    Rome, Lazio, 00168, Italy

  • Polyclinique Bordeaux Nord Aquitaine

    Bordeaux, 33077, France

  • Prof. Dr. Cemil Tascioglu City Hospital

    Istanbul, 34384, Turkey (Türkiye)

  • Pronutrir - suporte nutricional e quimioterapia ltda.

    Fortaleza, Ceará, 60810-180, Brazil

  • Przychodnia Lekarska KOMED, Roman Karaszewski

    Konin, 62-500, Poland

  • Queens Hospital Cancer Center

    Jamaica, New York, 11432, United States

  • Rajavithi Hospital

    Bangkok, 10400, Thailand

  • Rajiv Gandhi Cancer Inst.&Research Center

    New Delhi, National Capital Territory of Delhi, 110085, India

  • Ramathibodi Hospital

    Bangkok, 10400, Thailand

  • Rizk Hospital

    Beirut, 0, Lebanon

  • Royal Cornwall Hospital

    Truro, TR1 3LJ, United Kingdom

  • Royal Preston Hosp

    Preston, PR2 9HT, United Kingdom

  • Royal United Hospital

    Bath, BA1 3NG, United Kingdom

  • Sahyadri Super Specialty Hospital Hadapsar

    Pune, Maharashtra, 411028, India

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Semmelweis Egyetem;Onkológiai Profil (Belgyógyászati és Onkológiai Klinika)

    Budapest, 1082, Hungary

  • Seoul St Mary's Hospital

    Seoul, 06591, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, 03722, South Korea

  • Shandong Cancer Hospital

    Jinan, 250117, China

  • Sichuan Cancer Hospital

    Chengdu, 610041, China

  • Singleton Hospital

    Swansea, SA2 8QA, United Kingdom

  • Sohag Oncology Center

    Cairo, Egypt

  • Somogy Varmegyei Kaposi Mor Oktato Korhaz

    Kaposvár, 7400, Hungary

  • Songklanagarind Hospital

    Songkhla, 90110, Thailand

  • Sozialstiftung Bamberg, Klinikum am Bruderwald, Gynäkologie

    Bamberg, 96049, Germany

  • Sultan Qaboos Comprehensive Cancer Care & Research Center

    Muscat, Oman

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • Swedish Cancer Institute - Edmonds Campus

    Edmonds, Washington, 98026, United States

  • Swedish Cancer Institute - Issaquah

    Issaquah, Washington, 98029, United States

  • Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu

    Późna, 60-569, Poland

  • Szpital Wojewódzki im. Miko?aja Kopernika

    Koszalin, 75-581, Poland

  • TATA Medical Centre

    Kolkata, West Bengal, 700156, India

  • Taipei Veterans General Hospital Office of General Surgery

    Taipei, 11217, Taiwan

  • Tata Memorial Hospital

    Mumbai, Maharashtra, 400012, India

  • Tawam Hospital

    Al Ain City, 15258, United Arab Emirates

  • Texas Oncology - DFW

    Dallas, Texas, 75246, United States

  • Texas Oncology - El Paso

    El Paso, Texas, 79902, United States

  • The Aga Khan University-Kenya.

    Nairobi, 00100, Kenya

  • The First Affiliated Hospital Of Jinzhou Medical University

    Jinzhou, 121001, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, 110001, China

  • The First Affiliated Hospital of Xian Jiao Tong University

    Xi'an, 710061, China

  • The First Hospital of Jilin University

    Changchun, 130021, China

  • The Tumor Hospital of Xinjiang Medical University

    Ürümqi, 830000, China

  • Tianjin Cancer Hospital

    Tianjin, 300060, China

  • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi

    Edirne, 22030, Turkey (Türkiye)

  • UZ Gent

    Ghent, 9000, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, 3000, Belgium

  • Uganda Cancer Institute

    Kampala, 88560, Uganda

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, 430023, China

  • University Hospital North Tees

    Cleveland, TS19 8PE, United Kingdom

  • Universitätsklinik Tübingen

    Tübingen, 72076, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum des Saarlandes

    Homburg/Saar, 66424, Germany

  • Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii

    Gdansk, 80-214, Poland

  • Vall d'Hebron Institute of Oncology (VHIO), Barcelona

    Sant Andreu de la Barca, Barcelona, 08740, Spain

  • West Cancer Center

    Germantown, Tennessee, 38138, United States

  • West China Hospital - Sichuan University

    Chengdu, 610047, China

  • Wits Donald Gordon Clinical Trial Centre

    Parktown, Johannesburg, 2193, South Africa

  • Ysbyty Gwynedd Hospital

    Bangor, LL57 2PW, United Kingdom

  • Yunnan Cancer Hospital

    Kunming, 650118, China

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

  • Zhejiang Provincial People?s Hospital

    Hangzhou, 310014, China

  • the First Affiliated Hospital of Bengbu Medical College

    Bengbu, 233000, China

  • Ärztehaus am Bahnhofsplatz

    Hildesheim, 31134, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.